Oligonucleotides for modulating the effects of cytomegalovirus infections

• US 5,591,720 A
• Filed: 11/19/1992
• Issued: 01/07/1997
• Est. Priority Date: 08/16/1990
• Status: Expired due to Term

• Current Assignee: ISIS Pharmaceuticals Incorporated
• Original Assignee: ISIS Pharmaceuticals Incorporated
• Inventors: Draper, Kenneth G., Anderson, Kevin P.
• Primary Examiner(s): Zitomer, Stephanie W.
• Application Number:
  US07/927,506
• Time in Patent Office: 1,510 Days
• Field of Search: 536/24.5, 514/44
• US Class Current: 514/44.00A
• CPC Class Codes: A61K 31/711 Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 15/1133 against herpetoviridae, e.g. HSV
• CPC Class Codes: C12N 2310/315 Phosphorothioates
• CPC Class Codes: C12N 2310/321 2'-O-R Modification
• CPC Class Codes: C12N 2310/322 2'-R Modification
• CPC Class Codes: C12N 2310/3521 Methyl
• CPC Class Codes: C12N 2710/16122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 9/1252 DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
• CPC Class Codes: C12Q 1/705 for herpetoviridae, e.g. herpes simplex, varicella zoster

Abstract

Compositions and methods for modulating the effects of cytomegalovirus (CMV) infections are disclosed, comprising contacting CMV mRNA with an oligonucleotide or oligonucleotide analog which can bind with at least portions of the CMV RNA. In accordance with the preferred embodiments, oligonucleotides or oligonucleotide analogs are designed to bind with portions of the CMV mRNAs which code for the IE1, IE2 or DNA polymerase proteins. In accordance with a preferred embodiment, methods of treatment of human cytomegalovirus are disclosed.

Claims

1. An oligonucleotide or oligonucleotide analog having 15 to 50 bases fully complementary to a target DNA or corresponding RNA or pre-messenger RNA sequence wherein said oligonucleotide is selected from group consisting of SEQ ID NO:

s 3-21, 23 and 24 and said oligonucleotide analog is selected from the group consisting of;

modified SEQ ID NO;

s 3-21, 23 and 24 as set forth in Table 2.

2. A method for inhibiting replication of cytomegalovirus comprising contacting cells in vitro infected with CMV with an oligonucleotide analog fully complementary to a target DNA or corresponding RNA or pre-messenger RNA sequence wherein said oligonucleotide analog is selected from the group consisting of:

modified SEQ ID NO;

s 3-21, 23 and 24 as set forth in Table 2.